Clinical trials: Gastrointestinal Tract
Suspected or Confirmed COVID-19
NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients
This open-label, randomized, and controlled clinical trial aims to determine the feasibility and effectiveness of using NBT-NM108, a novel botanical-based fixed-combination drug, to modulate the gut microbiota and treat…
- Trial name
- COVGUT20 (NCT04540406)
- Testing
- NBT-NM108, Usual Care Only
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Notitia Biotechnologies Company
Pneumonia, Ventilator-Associated, Pneumonia, Bacterial
A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia
The purpose of this study is to assess the safety and tolerability of doripenem compared to imipenem in Ventilator-assisted pneumonia and complicated Intra-abdominal Infection.
- Conditions
- Pneumonia, Ventilator-Associated, Pneumonia, Bacterial, Pneumonia, Abdominal Abscess
- Trial name
- NCT00515034
- Testing
- Imipenem/cilastatin, Doripenem
- Volunteers
- 146 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Esophageal Cancer, Lung Cancer
Case Analysis on Real Life Incidence of Photodynamic Therapy (PDT) Safety Outcomes
Three main adverse reactions, namely photosensitivity (reaction that is similar to sunburn), oesophageal stenosis (narrowing or closure of the food pipe), perforation of the treated area (a tear or puncture of the tissue), have…
- Conditions
- Esophageal Cancer, Lung Cancer, Barrett's Esophagus
- Trial name
- CALIPSO (NCT01203163)
- Sponsor
- Pinnacle Biologics Inc.
Cystic Fibrosis
A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation
To evaluate the efficacy of ivacaftor treatment, as measured by lung clearance index (LCI), in subjects with cystic fibrosis (CF) who have a specified CF transmembrane conductance regulator (CFTR) gating mutation
- Trial name
- NCT02742519
- Testing
- ivacaftor
- Where
- 6 sites in Australia, Canada and 1 more
- Volunteers
- 14 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Gallbladder Disease
SILS™ Port Laparoscopic Cholecystectomy Post Market Study
The objectives of this trial are: 1. to assess the feasibility and safety of performing SILS™ Port Laparoscopic Cholecystectomy 2.
- Trial name
- NCT00832767
- Testing
- SILS™ port laparoscopic cholecystectomy, Four Port Laparoscopic Cholecystectomy
- Where
- 10 sites in United States, Italy and 1 more
- Volunteers
- 202 people
- Sponsor
- Medtronic - MITG
Type 2 Diabetes, Diabetes Mellitus Type 2
AIM-MET: AI-Guided Microbiome-Targeted Nutrition for Glycemic Improvement in Type 2 Diabetes
AIM-MET is a randomized clinical study testing whether a fixed microbiome-targeted nutritional product can improve blood sugar control in adults with type 2 diabetes when used in addition to usual stable diabetes treatment.
- Trial name
- AIM-MET (NCT07622628)
- Testing
- Microbiome-targeted oral food supplement
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- ENBIOSIS BIOTECHNOLOGIES
Appendicitis, Cholecystitis
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
This is a study of the safety and efficacy of tigecycline to ceftriaxone sodium plus metronidazole in hospitalized subjects with cIAI. Subjects will be followed for efficacy through the test-of-cure assessment.
- Conditions
- Appendicitis, Cholecystitis, Diverticulitis, Intra-Abdominal Abscess
- Trial name
- NCT00230971
- Testing
- tigecycline, ceftriaxone plus metronidazole
- Where
- 68 sites in Australia, China and 17 more
- Volunteers
- 473 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hepatocellular Carcinoma, Renal Cell Carcinoma
Safety Study of Cord Blood-derived Cytokine-induced Killer Cells in Patients With Solid Tumor After Radical Resection
Cytokine-induced killer (CIK) cells are a heterogeneous subset of ex-vivo expanded T lymphocytes which present a mixed T-NK phenotype and are endowed with a major histocompatibility complex-unrestricted antitumor activity.
- Conditions
- Hepatocellular Carcinoma, Renal Cell Carcinoma, Lung Cancer
- Trial name
- NCT01914263
- Testing
- cytokine induced killer cell
- Where
- 3 sites in China
- Volunteers
- 40 people
- Sponsor
- Alliancells-PuRui Biocience Co., Ltd.
Hepatitis C, Chronic
Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection
This study was designed to assess the safety and efficacy of multiple interferon-free treatment regimens of sofosbuvir (Sovaldi™; GS-7977; PSI-7977) and GS-0938 (PSI-352938) alone and in combination, with and without ribavirin…
- Trial name
- QUANTUM (NCT01435044)
- Testing
- Sofosbuvir, GS-0938, RBV
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 239 people
- Sponsor
- Gilead Sciences
Metastatic Gastric Cancer, Metastatic Breast Cancer
Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects
The purpose of this clinical study is to assess the safety and tolerability and efficacy of active immunotherapy with dose escalation and cohort expansion of OBI-833 in advanced/metastatic gastric, lung, colorectal, or breast…
- Conditions
- Metastatic Gastric Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Lung Cancer
- Trial name
- NCT02310464
- Testing
- OBI-833/OBI-821
- Where
- 4 sites in Taiwan
- Volunteers
- 25 people
- Sponsor
- OBI Pharma, Inc
Breast Cancer, Lung Cancer
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.
- Conditions
- Breast Cancer, Lung Cancer, Hepatocellular Cancer, Colorectal Cancer
- Trial name
- NCT02947165
- Testing
- NIS793, PDR001
- Where
- 12 sites in United States, Austria and 7 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer, Non-Small Cell Lung Cancer
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with…
- Conditions
- Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer
- Trial name
- NCT07578571
- Testing
- IM-1617
- Where
- 4 sites in United States
- Volunteers
- 175 people
- Sponsor
- Immunome, Inc.
Advanced Solid Tumors, HER2 Mutation
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety…
- Trial name
- panSOHO (NCT06760819)
- Testing
- BAY2927088
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 111 people
- Sponsor
- Bayer
Solid Tumor, Adult, Triple Negative Breast Cancer
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced…
- Conditions
- Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma
- Trial name
- NCT04282044
- Testing
- CRX100 suspension for infusion, Fludarabine, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- BioEclipse Therapeutics
Cystic Fibrosis, Burkholderia Infections
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection
The purpose of this research study was to determine if an experimental drug called Aztreonam for Inhalation Solution (AZLI) was safe and effective to treat Burkholderia lung infections in patients with cystic fibrosis (CF).
- Trial name
- NCT01059565
- Testing
- AZLI
- Where
- 35 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Gilead Sciences
Asthma
Adult Asthmatics and Acid Reflux
The purpose of this study is to assess the efficacy and safety of Nexium in the treatment of subjects with persistent asthma believed to have acid reflux as a contributory factor to control of their asthma.
- Trial name
- NCT00628953
- Testing
- Esomeprazole
- Volunteers
- 1,400 people
- Sponsor
- AstraZeneca
Biliary Tract Cancer
A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer
This is a Phase Ib, open-label,single-arm, clinical study, aiming to investigate the safety, tolerability and pharmacokinetics of ZKAB001 (a fully human monoclonal antibody targeting the Programmed Death - Ligand 1 (PD-L1)…
- Trial name
- NCT04608786
- Testing
- ZKAB001 5mg/kg, Capecitabine
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Lee's Pharmaceutical Limited
Advanced Solid Tumor, Melanoma
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors.
- Conditions
- Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
- Trial name
- NCT06172478
- Testing
- HER3-DXd
- Where
- 96 sites in United States, Australia and 14 more
- Volunteers
- 740 people
- Sponsor
- Daiichi Sankyo
Follow-on Formula, Infant
Effect of follow-on Formula on the Gut Microbiota of Healthy Infants.
This study investigates the effects of follow-on formula in infants aged 6-9 months over a 12-week period. After parents give consent, their baby's feeding habits, stool characteristics, and any illnesses or medication use will…
- Conditions
- Follow-on Formula, Infant, Faeces, Gut Microbiota
- Trial name
- FUNTASTIC (NCT07207109)
- Testing
- Test: Follow-on formula with synbiotics, Control: Regular follow-on formula
- Where
- 2 sites in Indonesia
- Volunteers
- 268 people, healthy volunteers welcome
- Sponsor
- Nutricia Research
Renal Cell Carcinoma, Gastric Cancer
A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)
Study HC-404-FCP-2011 is a first in human, Phase 1a, multi-center, open-label study to establish the maximum tolerated dose (MTD) and evaluate the safety and tolerability of oral dosing of HC-5404-FU in a dose-escalating fashion.
- Conditions
- Renal Cell Carcinoma, Gastric Cancer, Metastatic Breast Cancer, Small-cell Lung Cancer
- Trial name
- NCT04834778
- Testing
- HC-5404-FU
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- HiberCell, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.